The incidence of opioid use disorders (OUDs) has increased to near-epidemic proportions.
While maintenance with long-acting opioids such as methadone or buprenorphine represents an
effective treatment strategy, it may be unacceptable to many individuals. As a result,
long-acting injectable naltrexone (XR-NTX), an antagonist medication that blocks the effects
of opioids for at least 4 weeks, is now indicated for relapse prevention following
detoxification. This randomized, controlled trial aims to test the efficacy of a glutamate
modulator at facilitating a rapid non-opioid based naltrexone induction.